Want to see NSRX full AI Analyst Report?
Top Page
Nasus Pharma Ltd.
(NSRX)
Select Model
Select Model
Rating:44Neutral
Price Target:
$3.00
▼(-26.83% Downside)
Action:N/A
Date:10/17/26
The score is held down primarily by weak financial performance (no revenue, widening losses, and sharply higher cash burn in 2025), with bearish technical conditions (price below key moving averages and negative MACD) reinforcing near-term risk. Balance-sheet improvement in 2025 (very low debt and positive equity) provides some support, but valuation remains constrained by ongoing losses and no dividend yield data.
Positive Factors
NS002 regulatory progress
FDA clearance removes a major regulatory barrier and allows Nasus to advance NS002 into a pivotal U.S. study. Progress toward late-stage data creates a clearer development path for its lead asset and could strengthen the company’s commercial prospects if efficacy and safety are demonstrated.
Negative Factors
No commercial revenue
Nasus has not yet demonstrated commercial revenue generation, and losses widened materially in 2025. This indicates that the business remains dependent on successful clinical execution and future financing rather than an established operating model that can independently support ongoing development.
Read all positive and negative factors
Positive Factors
Negative Factors
NS002 regulatory progress
FDA clearance removes a major regulatory barrier and allows Nasus to advance NS002 into a pivotal U.S. study. Progress toward late-stage data creates a clearer development path for its lead asset and could strengthen the company’s commercial prospects if efficacy and safety are demonstrated.
Read all positive factors
Nasus Pharma Ltd. (NSRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$35.84M
Dividend YieldN/A
Average Volume (3M)19.67K
Price to Earnings (P/E)―
Beta (1Y)1.30
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees7
SectorGeneral
Sector StrengthN/A
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,710,808
10 Day Avg. Volume15,601
30 Day Avg. Volume19,674
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)26.48
Price to Sales (P/S)0.00
P/FCF Ratio-14.86
Enterprise Value/Market Cap0.97
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.84
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Nasus Pharma Ltd. Business Overview & Revenue Model
Company Description
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and pub...
Nasus Pharma Ltd. Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
38
Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -7.18M | -4.90M | -1.52M | -956.00K | -2.13M |
| Net Income | -10.30M | -5.86M | -1.53M | -1.05M | -1.71M |
Balance Sheet | |||||
| Total Assets | 12.45M | 5.00M | 717.00K | 444.00K | 417.00K |
| Cash, Cash Equivalents and Short-Term Investments | 11.82M | 4.29M | 284.00K | 193.00K | 154.00K |
| Total Debt | 103.00K | 118.00K | 1.80M | 2.46M | 1.57M |
| Total Liabilities | 1.45M | 2.24M | 3.93M | 4.24M | 3.20M |
| Stockholders Equity | 11.00M | 2.77M | -3.21M | -3.80M | -2.79M |
Cash Flow | |||||
| Free Cash Flow | -3.36M | -4.93M | -665.00K | -1.03M | -1.21M |
| Operating Cash Flow | -3.36M | -4.92M | -665.00K | -1.03M | -1.21M |
| Investing Cash Flow | -1.23M | -3.01M | 0.00 | 0.00 | -160.00K |
| Financing Cash Flow | 7.08M | 8.92M | 770.00K | 1.05M | 1.24M |
Nasus Pharma Ltd. Technical Analysis
Negative
4.10
Price Trends
3.62
Negative
3.39
Negative
3.78
Negative
Market Momentum
-0.13
Positive
33.13
Neutral
16.07
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NSRX, the sentiment is Negative. The current price of 4.1 is above the 20-day moving average (MA) of 3.48, above the 50-day MA of 3.62, and above the 200-day MA of 3.78, indicating a bearish trend. The MACD of -0.13 indicates Positive momentum. The RSI at 33.13 is Neutral, neither overbought nor oversold. The STOCH value of 16.07 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NSRX.
Nasus Pharma Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | $3.21M | -0.03 | -134.03% | ― | ― | 93.96% | |
48 Neutral | $4.73M | -1.70 | -40.62% | ― | 33.30% | 40.59% | |
44 Neutral | $35.84M | -2.98 | -158.83% | ― | ― | ― | |
43 Neutral | $388.36K | ― | -26.63% | ― | 30.12% | -165.46% | |
42 Neutral | $6.78M | -0.04 | 952.76% | ― | -21.49% | 84.62% |
* General Sector Average
NSRX
Nasus Pharma Ltd.
3.06
-4.54
-59.74%
AIM
AIM ImmunoTech
0.17
-2.38
-93.33%
SCNI
Scinai Immunotherapeutics
0.61
-13.59
-95.70%
XBIO
Xenetic Biosciences
2.02
-1.84
-47.67%
GRI
GRI Bio
1.47
-55.37
-97.41%
Nasus Pharma Ltd. Corporate Events
Nasus Pharma Shareholders Approve Most Proposals at October Annual and Special Meeting
Oct 8, 2026
On October 8, 2026, Nasus Pharma Ltd. held its Annual and Special General Meeting of Shareholders, where a valid quorum was present and investors approved all agenda items except Proposal No. 4, which failed to receive the required majority. The o...
Nasus Pharma Sets Up $8.5 Million At-the-Market Equity Program to Fund Clinical Pipeline
Sep 18, 2026
On September 18, 2026, Nasus Pharma Ltd. entered into an at-the-market sales agreement with BTIG LLC, allowing the company to issue and sell ordinary shares from time to time under its existing F-3 shelf registration. The arrangement gives Nasus f...
Nasus Pharma Wins FDA Clearance to Begin NS002 Anaphylaxis Trial
Sep 14, 2026
On September 14, 2026, Nasus Pharma announced that the U.S. Food and Drug Administration cleared its Investigational New Drug application for NS002, an intranasal epinephrine powder for treating anaphylaxis, enabling the company to initiate a new ...
Nasus Pharma Sets October 8, 2026 Shareholder Meeting to Vote on Governance, Executive Pay and Option Pool
Sep 4, 2026
Nasus Pharma Ltd. has called an Annual and Special General Meeting of shareholders for October 8, 2026 in Tel Aviv, with shareholders of record as of September 14, 2026 eligible to participate and vote. The company filed a Form 6-K on September 4,...
Nasus Pharma Names Interim CFO as Longtime Finance Chief Resigns
Aug 19, 2026
Nasus Pharma Ltd. reported on August 19, 2026, that Chief Financial Officer Eyal Rubin has resigned to pursue a role outside the life sciences industry, with his departure effective September 18, 2026. The company emphasized that Rubin’s dec...
Nasus Pharma Boosts Cash and Equity in First-Half 2026 Filing
Aug 17, 2026
Nasus Pharma filed a Form 6-K in August 2026, providing unaudited condensed consolidated financial statements and management discussion for the six months ended June 30, 2026. The filing also includes a same-day press release on its first-half 202...
Nasus Pharma Installs Industry Veteran Brendan O’Grady as CEO to Steer Next Growth Phase
Jul 28, 2026
Nasus Pharma Ltd., a clinical-stage biopharmaceutical company specializing in intranasal powder therapies and lead asset NS002 for anaphylaxis, is expanding a pipeline of rapid, patient-friendly intranasal treatments across several therapeutic are...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.